AXSM Axsome Therapeutics, Inc. Insider Trading

AXSM CEO Herriot Tabuteau sold 49.7K shares ($12.0M) at $241.01; retains 7.2K shares plus 99,330 stock options

CEO Herriot Tabuteau executed a pre-arranged 10b5-1 trading plan sale on 2026-06-09, disposing of 49,670 shares valued at $11,970,966.70 while retaining 7,229 non-derivative shares and derivative holdings of 99,330 shares via stock options. The sale occurred at $241.01, near the 52-week high of $242.41 and against a backdrop of 13.0% gains over 30 days and 54.0% gains over 90 days. Axsome remains unprofitable (full-year net income: $-64,542,000.00) despite strong revenue growth of 65.6% year-over-year. His prior five trades at this ticker show mixed post-sale performance (30-day range -11.6% to +20.6%, 90-day range -1.6% to +11.3%), with no consistent directional pattern, making this scheduled sale a neutral data point on conviction rather than a discretionary signal.

CFO Nick Pizzie sold 33,000 AXSM shares at $240.09 (total $7.9M) under 10b5-1 plan; holds 42,867 shares post-sale plus 72,000 stock options.

CFO Nick Pizzie sold 33,000 shares (33.0K shares) of Axsome for $7,922,970.00 (total value), reducing his non-derivative holdings from 75,867 to 42,867 shares, a reduction of -43.5%. This transaction was executed under a pre-arranged 10b5-1 trading plan and therefore was scheduled, not discretionary. Notably, prior sales by this insider at AXSM show mixed near-term outcomes: his January 2026 sale returned -2.2% at 30 days, while his two February 2025 sales returned -7.0% and -6.1% at 30 days respectively. The company remains unprofitable (net income of $-64,542,000.00 for the latest quarter) despite strong revenue growth of +65.6% year-over-year, which presents a context of expansion without current profitability. The insider retains substantial derivative holdings of 72,000 stock options, indicating continued equity exposure to the company.

Director Mark Coleman sold 17,537 shares over 3 days (May 29–Jun 2) for $4,019,470.43 via scheduled 10b5-1 plan at AXSM

Mark Coleman, a Director at Axsome Therapeutics, executed 3 separate sales totaling 17,537 shares for $4,019,470.43 between May 29 and June 2, 2026, reducing his holdings by 37.2% to 29,603 shares post-transaction. This disposition was effected through a pre-arranged 10b5-1 trading plan—a scheduled, non-discretionary mechanism—so the timing and execution reflect contractual commitment rather than a discretionary market timing decision. The company remains unprofitable with a full-year net income of $-64,542,000.00, though it is growing revenue at an annual rate of +65.6%. Across his prior 3 sales at this ticker, Coleman's average 90-day return was +45.6%, indicating that his prior open-market dispositions at AXSM were followed by stock appreciation; however, the current stock price of $245.64 is only 1.3% above its 52-week high of $242.41, and this scheduled 10b5-1 execution carries no forward-looking signal independent of the plan's predetermined terms.